Results for tag: "Apolipoprotein A-I"

Apolipoprotein A-I (ApoA-I) is a protein found in the blood that plays an important role in the metabolism of lipids. It is a major component of high-density lipoprotein (HDL) and is involved in the reverse cholesterol transport process, which helps to reduce the risk of cardiovascular disease. ApoA-I is also used as a biomarker for cardiovascular risk, and is the target of several drugs used to treat cardiovascular disease. ApoA-I drugs are used to reduce the risk of cardiovascular disease by increasing the levels of HDL in the blood. These drugs are typically administered as an injection or infusion, and are used in combination with other treatments such as statins and lifestyle modifications. The ApoA-I market is a rapidly growing segment of the cardiovascular drugs market, driven by the increasing prevalence of cardiovascular disease and the need for effective treatments. The market is expected to continue to grow in the coming years, as new drugs are developed and approved for use. Some of the major companies in the ApoA-I market include Amgen, Sanofi, Regeneron, and Pfizer. Show Less Read more